juxtaglomerular cells

Juxtaglomerular cells are specialized, granulated smooth muscle-like cells derived from the tunica media of the afferent arteriole (and to a lesser extent, efferent arteriole) as it enters the glomerulus. They act as baroreceptors, sensing decreased stretch/pressure in the afferent arteriole, which signals decreased renal perfusion. They also respond to signals from the macula densa (specialized cells of the distal convoluted tubule) which detects low NaCl delivery, triggering release of prostaglandins that stimulate JG cells to release renin. Additionally, JG cells possess β1-adrenergic receptors, so increased sympathetic tone (e.g., during hypotension or hemorrhage) directly stimulates renin release.

Renin released from JG cells cleaves angiotensinogen (produced by the liver) to angiotensin I, which is then converted to angiotensin II by ACE (mainly in the lungs). Angiotensin II causes vasoconstriction, stimulates aldosterone release from the adrenal cortex (zona glomerulosa), promotes ADH release, and increases sympathetic activity—all leading to increased blood pressure and volume.

Clinical correlations: - Renal artery stenosis causes decreased perfusion pressure sensed by JG cells, leading to increased renin secretion, hypertension, and unequal kidney sizes. - NSAIDs inhibit prostaglandin synthesis, reducing renin release and afferent arteriole vasodilation, which can precipitate acute kidney injury, especially in volume-depleted states. - Beta-blockers decrease renin release by blocking β1 receptors on JG cells, useful in hypertension management. - JG cell tumors (reninomas) cause secondary hypertension with hyperreninemia and hyperaldosteronism. - ACE inhibitors and ARBs block the RAAS pathway downstream, used to treat hypertension and reduce proteinuria in diabetic nephropathy. - Understanding this pathway is essential for interpreting cases of hypertension, edema, and electrolyte disturbances on USMLE exams.